Radium-223 dichloride in clinical practice: a review

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 10, 2016, Pages 1896-1909

  Florimonte, Luigia ^a   Dellavedova, Luca ^b   Maffioli, Lorenzo Stefano ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Ospedale di Legnano   (Italy)

^c Nuclear Medicine and Multi Hospital Oncology Department   (Italy)

Author keywords

Bone metastasis; Overall survival; Radium 223 dichloride; Emitters

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM 177; PHOSPHATE P 32; RADIUM CHLORIDE RA 223; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM CHLORIDE SR 89; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM;

BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; HEALTH ECONOMICS; HUMAN; MALE; OSTEOBLAST; OSTEOCLAST; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION SAFETY; RADIOISOTOPE THERAPY; REVIEW; BONE NEOPLASMS; COMORBIDITY; EVIDENCE BASED MEDICINE; MORTALITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION INJURY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

BONE NEOPLASMS; COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIATION INJURIES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84982730476     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3386-5     Document Type: Review

References (112)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer. 2003;98:1169–78.
3. Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. European Association of Urology; 2015. Available at: http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf. Accessed 19 April 2016.
4. Gartrell BA, Coleman R, Efstathiou E, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68:850–8. doi:10.1016/j.eururo.2015.06.039.
5. Lipton A, Uzzo R, Amato RJ, et al. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009;7 Suppl 7:S1–30.
6. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120–5.
7. Roodman GD. Mechanism of bone metastases. N Engl J Med. 2004;350:1655–64.
8. Ibrahim T, Flamini E, Mercatali L, et al. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116:1406–18.
9. Blacksburg SR, Witten MR, Haas JA. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Curr Treat Options Oncol. 2015;16:325.
10. Bienz M, Saad F. Management of bone metastases in prostate cancer: a review. Curr Opin Support Palliat Care. 2015;9:261–7.
11. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.
12. El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer. 2013;2013:210686. doi:10.1155/2013/210686.
13. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71.
14. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.
15. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.
16. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.
17. Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium. Cancer Biother Radiopharm. 2014;29(1):1–11.
18. Ariel IM, Hassouna H. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus. Int Surg. 1985;70:63–6.
19. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46:38S–47.
20. Den RB, Doyle LA, Knudsen E. Practical guide to the use of radium-223 dichloride. Can J Urol. 2014;21 Suppl 1:70–6.
21. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.
22. Mertens WC, Stitt L, Porter AT. Strontium-89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol. 1993;16(3):238–42.
23. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.
24. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357(9253):336–41.
25. Palmedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21(15):2869–75.
26. Turner JH, Claringbold PG, Hetherington EL, et al. A phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol. 1989;7(12):1926–31.
27. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–81.
28. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26(1):2–7.
29. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.
30. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27(15):2429–35.
31. Ando A, Ando I, Tonami N, et al. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998;19(6):587–91.
32. Chakraborty S, Das T, Banerjee S, et al. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23(2):202–13.
33. Agarwal KK, Singla S, Arora G, et al. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging. 2015;42(1):79–88.
34. Thapa P, Nikam D, Das T, et al. Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases. J Nucl Med. 2015;56(10):1513–9.
35. Guerra Liberal FD, Tavares AA, Tavares JM. Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. 2014;41(11):114101.
36. Hirao M, Hashimoto J, Yamasaki N, et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab. 2007;25:266–76.
37. Barensden GW. Responses of cultured cells, tumours and normal tissues to radiations of different linear energy transfer. In: Ebert M, Howard A, editors. Current topics in radiation research, vol. IV. Amsterdam, Netherlands: North-Holland; 1968. p. 293–356.
38. Tinganelli W, Ma NY, Von Neubeck C, et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res. 2013;54 Suppl 1:i23–30.
39. Seidl C. Radioimmunotherapy with α-particle-emitting radionuclides. Immunotherapy. 2014;6(4):431–58.
40. Miller BW, Frost SH, Frayo SL, et al. Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera. Med Phys. 2015;42(7):4094–105.
41. Gudkov SV, Shilyagina NYU, Vodeneev V, et al. Targeted radionuclide therapy of human tumors. Int J Mol Sci. 2015;28:17(1). doi:10.3390/ijms17010033
42. IAEA. Technical meeting on “Alpha emitting radionuclides and radiopharmaceuticals for therapy”. Available at: http://www-naweb.iaea.org/napc/iachem/working_materials/TM-44815-report-Alpha-Therapy.pdf - Accessed 20 April 2016.
43. Larsen RH, Henriksen G, Øyvind S. Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning. US6635234. Available at: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6635234.PN.&OS=PN/6635234&RS=PN/6635234. Accessed 20 April 2016.
44. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12:6250s–57s.
45. Wieder HA, Lassmann M, Allen-Auerbach MS, et al. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014;6(7):480–5.
46. Gholami Y, Zhu X, Fulton R, et al. Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level. Phys Med Biol. 2015;60:6087–96.
47. Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.
48. Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40:207–12.
49. Nilsson S, Larsen RH, Foss SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–9.
50. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.
51. Bayer HealthCare. Xofigo (radium Ra 223 dichloride) Injection, for intravenous use: highlights of prescribing information. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf. Accessed 20 April 2016.
52. Bayer HealthCare. Xofigo: radium Ra 223 dichloride Injection. 2015. Available at: http://www.xofigo-us.com/patient/index.php. Accessed 20 April 2016.
53. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
54. Dauer LT, Williamson MJ, Humm J, et al. Radiation safety considerations for the use of 223RaCl2 DE in men with castration-resistant prostate cancer. Health Phys. 2014;106(4):494–504.
55. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86.
56. Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–97.
57. Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11(1):20–6.
58. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738–46.
59. Nilsson S, Sartor O, Bruland OS, et al. Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]. J Clin Oncol. 2013;19 Suppl 6:5038.
60. Nilsson S, Tomblyn M, Cislo P, et al. Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study [abstract]. J Clin Oncol. 2014;32(5s):5069.
61. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.
62. Shirley M, McCormack PL. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs. 2014;74:579–86.
63. Ryan CJ, Saylor PJ, Everly JJ, et al. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. The Oncologist. 2014;19:1012–8.
64. Herranz UA, Fernandez Calvo O, Afonso FJ, et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015;15(3):339–48.
65. McGann S, Horton ER. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. Ann Pharmacother. 2015;49(4):469–76.
66. Turner PG, O’Sullivan JM. 223Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. Br J Radiol. 2015;88:20140752.
67. Chalhoub E, Chalouhy C, Sartor O. Treatment of skeletal metastases with 223Ra-chloride. Clin Transl Imaging. 2015;3:159–65.
68. Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: a therapy with 223Ra-dichloride. J Nucl Med. 2014;55:268–74.
69. Gartrell BA, Saad F. Pathologic fractures in patients with metastatic prostate cancer. Curr Opin Urol. 2014;24:595–600.
70. Graff JN, Beer TM. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging. 2014;31:873–82.
71. George D, Moul JW. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate. 2012;72:338–49.
72. Parker C, Gillessen S, Heidenreich A, et al. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77.
73. NCCN. NCCN Guidelines for Patients: Prostate Cancer. 2015. Available at: http://www.nccn.org/patients/guidelines/prostate/. Accessed 20 April 2016.
74. Vuong W, Sartor O, Pal SK. Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl. 2014;16:348–53.
75. Mukherji D, El Dika I, Temraz S, et al. Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer: role of radium-223. Ther Clin Risk Manag. 2014;10:373–80.
76. Gernone A, Bordonaro S, Tralongo P. Optimal sequence of bone target drugs in metastatic prostatic cancer. Expert Rev Anticancer Ther. 2015;15(8):923–9.
77. Borsò E, Boni G, Galli L, et al. Radium-223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. Future Oncol. 2015;11(2):323–31.
78. Todenhöfer T, Stenzl A, Hofbauer LC, et al. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202
79. Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 2015;12(6):340–56. doi:10.1038/nrurol.2015.90.
80. Dreicer R. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer. Can J Urol. 2014;21 Suppl 1:93–7.
81. Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17(9):799–804.
82. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43(1):79–86.
83. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34(7):1023–30.
84. Borsò E, Boni G, Pastina I, et al. Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2014;35(1):88–94.
85. Rose JN, Crook JM. The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2015;7(3):135–45.
86. Basch E, Loblaw EA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–48.
87. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?term=radium&show_down=Y. Accessed 20 April 2016.
88. European Union Clinical Trials Register. Available at: https://www.clinicaltrialsregister.eu. Accessed 20 April 2016.
89. Morris MJ, Higano C, Scher HI, et al. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: a phase 1/2a clinical trial. Ann Oncol. 2014;25 Suppl 4:iv255–79.
90. Finkelstein SE, Michalski JM, O’Sullivan JM, et al. EBRT use and safety with radium-223 dichloride in patients with CRPC and symptomatic bone metastases from the ALSYMPCA trial [abstract]. J Clin Oncol. 2015;33(7):182.
91. Roach 3rd M. Radium-223 vs. EBRT for multiple painful bone metastases: is less more? Oncology (Williston Park). 2014;28(4):297–8.
92. Jayasekera J, Onukwugha E, Bikov K, et al. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Pharmacoeconomics. 2014;32:173–91.
93. Yong C, Onukwugha E, Mullins CD. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Curr Opin Oncol. 2014;26:274–83.
94. Pani L. Riclassificazione del medicinale per uso umano «Xofigo», ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 576/2015). Gazzetta Ufficiale della Repubblica Italiana. General Series 2015, no. 121.
95. Readler LA. Xofigo (radium Ra 223 dichloride):. the first alpha particle-emitting radioactive agent for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. American Health and Drugs Benefits. Available at: http://www.ahdbonline.com/issues/2014/march-2014-volume-7-special-feature-fifth-annual-payers-guide-to-new-fda-approvals/1733-xofigo-radium-ra-223-dichloride-the-first-alpha-particle-emitting-radioactive-agent-for-the-treatment-of-castration-resistant-prostate-cancer-with-symptomatic-bone-metastases - Last accessed: October 19, 2015.
96. Guirgis HM. Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer [abstract]. J Clin Oncol. 2013;31 Suppl 6:200.
97. Renzulli JF 2nd, Collins J, Mega A. Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. J Multidiscip Healthc. 2015;8:279–86.
98. Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist’s perspective. Urology. 2015;85(4):717–24.
99. Takalkar A, Adams S, Subbiah V. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Exp Hematol Oncol. 2014;3:23.
100. Coleman R, Ak A, Naume B, et al. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat. 2014;145:411–8.
101. Silva SC, Wilson C, Woll PJ. Bone-targeted agents in the treatment of lung cancer. Ther Adv Med Oncol. 2015;7(4):219–28.
102. Chittenden SJ, Hindorf C, Parker CC, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics and dosimetry of radium-223 dichloride (223Ra dichloride) in patients with hormone refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56(9):1304–9.
103. Jadvar H, Challa S, Quinn D, et al. One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer. Cancer Biother Radiopharm. 2015;30(5):195–9.
104. Hindorf C, Chittenden S, Aksnes AK, et al. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun. 2012;33(7):726–32.
105. Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016;43:21–33.
106. Follacchio GA, Frantellizzi V, Pellegrini R, et al. Feasibility of 223Ra quantitative imaging for lesion dosimetry [abstract]. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):OP236.
107. Murray I, Chittenden SJ, Parker CC, et al. The potential of F-18 fluoride PET as a surrogate for radium-223 chloride lesion dosimetry in hormone refractory prostate cancer patients [abstract]. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):OP235.
108. Etchebehere EC, Araujo JC, Fox PS, et al. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56(8):1177–84.
109. Cook Jr G, Parker C, Chua S, et al. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res. 2011;1(1):4.
110. Miyazaki KS, Kuang Y, Kwee SA. Changes in skeletal tumor activity on (18)F-choline PET/CT in patients receiving (223)radium radionuclide therapy for metastatic prostate cancer. Nucl Med Mol Imaging. 2015;49(2):160–4.
111. Sakretz M, Kurth J, Schwarzenböck SM, et al. Automatic bone scan index for therapy response assessment of radium-223-dichloride (Ra-223) therapy in advanced prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(1 Suppl):P748.
112. Yu EY, Duan F, Muzi M, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56(3):354–60.